RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Minimal residual disease can now be considered an end point in trials leading to accelerated approvals by the FDA for multiple myeloma.

Investigators also look to assess linvoseltamab in relapsed/refractory multiple myeloma as part of the phase 3 LINKER-MM3 trial.